Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18889412 | 0.92 | POLB (0.54) | POLBNPC1RAB9AGFERSMN1; SMN2 | |
| SCHEMBL18889384 | 0.92 | POLB (0.60) | POLBNPC1RAB9AGFERSMN1; SMN2 | |
| SCHEMBL18889383 | 0.91 | KMT2A (0.55) | POLBNPC1RAB9AGFERSMN1; SMN2 | |
| SCHEMBL18889419 | 0.91 | POLB (0.49) | POLBNPC1RAB9AGFERSMN1; SMN2 | |
| SCHEMBL17444559 | 0.88 | POLB (0.59) | POLBNPC1RAB9AGFERSMN1; SMN2 | |
| SCHEMBL18889395 | 0.85 | KMT2A (0.51) | POLBNPC1RAB9AGFERSMN1; SMN2 | |
| SCHEMBL18889417 | 0.85 | POLB (0.54) | POLBNPC1RAB9AGFERSMN1; SMN2 | |
| SCHEMBL18889402 | 0.84 | ALDH1A1 (0.51) | POLBNPC1RAB9AGFERSMN1; SMN2 | |
| SCHEMBL18889385 | 0.84 | POLB (0.58) | POLBNPC1RAB9AGFERSMN1; SMN2 | |
| SCHEMBL18889397 | 0.84 | KMT2A (0.54) | POLBNPC1RAB9AGFERSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152226-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | POLB 1177/4885NPC1 4426/4885RAB9A 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.